Evidence map›Paper›PMID 30484020›Full record

ArticleChinese journal of integrative medicine2019

Curcumin Reverses 5-Fluorouracil Resistance by Promoting Human Colon Cancer HCT-8/5-FU Cell Apoptosis and Down-regulating Heat Shock Protein 27 and P-Glycoprotein.

Wen-Ting He, Yan-Hua Zhu, Tong Zhang, Patima Abulimiti, Fan-Ye Zeng, Li-Ping Zhang, Ling-Juan Luo, Xin-Mei Xie, Hong-Liang Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Chinese journal of integrative medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Natural Polyphenols for Treatment of Colorectal Cancer.Molecules (Basel, Switzerland) · 2022
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Is Curcumin the Answer to Future Chemotherapy Cocktail?Molecules (Basel, Switzerland) · 2021
    Review
  17. Article
  18. Review
  19. Review
  20. Updated Review on the Role of Curcumin in Gastrointestinal Cancers.Advances in experimental medicine and biology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Wen-Ting HeSecond Department of Oncology, Traditional Chinese Medicine Hospital of Xinjiang Uyghur Autonomous Region, Uyghur, 830000, China.
Yan-Hua ZhuSecond Department of Oncology, Traditional Chinese Medicine Hospital of Xinjiang Uyghur Autonomous Region, Uyghur, 830000, China.
Tong ZhangDepartment of Oncology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
Patima AbulimitiSecond Department of Oncology, Traditional Chinese Medicine Hospital of Xinjiang Uyghur Autonomous Region, Uyghur, 830000, China.
Fan-Ye ZengSecond Department of Oncology, Traditional Chinese Medicine Hospital of Xinjiang Uyghur Autonomous Region, Uyghur, 830000, China.
Li-Ping ZhangSecond Department of Oncology, Traditional Chinese Medicine Hospital of Xinjiang Uyghur Autonomous Region, Uyghur, 830000, China.
Ling-Juan LuoSecond Department of Oncology, Traditional Chinese Medicine Hospital of Xinjiang Uyghur Autonomous Region, Uyghur, 830000, China.
Xin-Mei XieSecond Department of Oncology, Traditional Chinese Medicine Hospital of Xinjiang Uyghur Autonomous Region, Uyghur, 830000, China.
Hong-Liang ZhangSecond Department of Oncology, Traditional Chinese Medicine Hospital of Xinjiang Uyghur Autonomous Region, Uyghur, 830000, China. xjzyyzhl@sina.com.
Xinjiang Uygur Autonomous Region Uygur Medicine Hospital · CNXiyuan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the potential mechanisms that curcumin reverses 5-fluorouracil (5-FU) multidrug resistance (MDR).

methodsCell growth and the inhibitory rate of curcumin (2-25 μg/mL) and/or 5-FU (0.05-1000 μg/mL) on human colon cancer HCT-8 and HCT-8/5-FU (5-FU-resistant cell line) were determined using cell counting kit-8 (CCK-8) assay. Apoptosis and cell cycle after 5-FU and/or curcumin treatment were detected by flow cytometry (FCM) and transmission electron microscopy (TEM). The expression of the multidrug resistance related factors p-glycoprotein (P-gp) and heat shock protein 27 (HSP-27) genes and proteins were analyzed by reverse transcription polymerase chain reaction (RT-PCR) and Western blotting (WB), respectively.

resultsThe inhibitory rate of curcumin or 5-FU on HCT-8 and HCT-8/5-FU cells proliferation at exponential phase were in a dosedependent manner, HCT-8 cell line was more sensitive to curcumin or 5-FU when compared the inhibitory rate of HCT-8/5-FU. The 50% inhibitory concentration (IC

conclusionsCurcumin can inhibit the proliferation of human colon cancer cells. Curcumin has the ability of reversal effects on the multidrug resistance of human colon cancer cells lines HCT-8/5-FU. Down-regulation of P-gp and HSP-27 may be the mechanism of curcumin reversing the drug resistance of HCT-8/5-FU to 5-FU.

Indexed as

ApoptosisATP Binding Cassette Transporter, Subfamily B, Member 1Cell CycleCell Line, TumorCell ProliferationColonic NeoplasmsCurcuminDown-RegulationDrug Resistance, NeoplasmDrug SynergismFluorouracilGene Expression Regulation, NeoplasticHSP27 Heat-Shock ProteinsHumansRNA, MessengerATP Binding Cassette Transporter, Subfamily B, Member 1CurcuminFluorouracilHSP27 Heat-Shock ProteinsRNA, Messenger5-fluorouracilChinese medicinecolon cancercurcuminHCT-8HCT-8/5-FUHSP-27multidrug resistanceP-gp

Identifiers

PMID30484020
OpenAlexW2903222327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.